Synaffix’ GlycoConnect platform shows promise for neuromuscular disease treatment
Synaffix’ GlycoConnect platform shows promise for neuromuscular disease treatment.
Synaffix’ GlycoConnect platform shows promise for neuromuscular disease treatment
Synaffix’ GlycoConnect platform shows promise for neuromuscular disease treatment.
Leaders in Life Sciences – #33 Wiesje van der Flier
In the Leaders in Life Sciences podcast, our host Henk Jan Out engages in conversations with leaders of now and soon in the life sciences sector. This episode’s guest is Wiesje van der Flier.
Leaders in Life Sciences – #32 Haifen Hu
In the Leaders in Life Sciences podcast, our host Henk Jan Out engages in conversations with leaders of now and soon in the life sciences sector. This episode’s guest is Haifen Hu.
Leaders in Life Sciences – #31 Eliane Schutte
In the Leaders in Life Sciences podcast, our host Henk Jan Out engages in conversations with leaders of now and soon in the life sciences sector. This episode’s guest is Eliane Schutte.
Citryll reaches Phase 1 trial milestone
Citryll completes patient dosing in the repeat dose stage of the Phase 1 trial for the novel anti-inflammatory candidate CIT-013.
Unveiling the importance of polymorphism in drug development: Insights from Ardena
Ardena shares the latest insights on the critical role of polymorphism in drug development. Learn why early-stage polymorph screens are essential, how they mitigate risks, and the innovative methods Ardena employs to ensure robust drug development.
Leaders in Life Sciences – #30 Koenraad Wiedhaup
In the Leaders in Life Sciences podcast, our host Henk Jan Out engages in conversations with leaders of now and soon in the life sciences sector. This episode’s guest is Koenraad Wiedhaup.
Leaders in Life Sciences – #29 Jan Paul Medema
In the Leaders in Life Sciences podcast, our host Henk Jan Out engages in conversations with leaders of now and soon in the life sciences sector. This episode’s guest is Jan Paul Medema.
or call
Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.